Andere Sprachen Neuronetics, Inc.

Aktien

A2JPMY

US64131A1051

STIM

Medizinische Ausrüstung

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 15.01.2026			% 5 Tage	Veränd. 1. Jan.
1.810 ^USD	+2.26%		-7.65%	+31.16%

04.11.	Neuronetics, Inc., Q3 2025 Earnings Call, Nov 04, 2025
04.11.	Neuronetics, Inc. legt Ergebnisse für das dritte Quartal und die ersten neun Monate zum 30. September 2025 vor	CI

Andere Sprachen

20.11.	Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference
12.11.	TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression
04.11.	Neuronetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
04.11.	Keith J. Sullivan Intends to Retire as Chief Executive Officer of Neuronetics, Inc. on June 30, 2026
04.11.	Keith J. Sullivan Intents to Retire as President of Neuronetics, Inc. on June 30, 2026
04.11.	Neuronetics, Inc. Provides Revenue Guidance for the Fourth Quarter 2025
04.11.	Neuronetics, Inc. Revises Earnings Guidance for the Full Year 2025
04.11.	Neuronetics: Q3 Earnings Snapshot
04.11.	Neuronetics : STIM Corporate Presentation November 2025
04.11.	Neuronetics Q3 revenue misses estimates
04.11.	Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan
31.10.25	Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
30.10.25	Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence
30.10.25	Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand Neurostar Access and Operational Excellence
21.10.25	Neuronetics to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call
22.09.25	Neuronetics, Inc.(NasdaqGM:STIM) added to S&P Global BMI Index
17.09.25	Neuronetics - New York Medicaid to cover TMS services for adults with MDD
17.09.25	New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)
06.08.25	Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05.08.25	Neuronetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
05.08.25	Neuronetics: Q2 Earnings Snapshot
05.08.25	Healthcare firm Neuronetics Q2 revenue beats estimates
05.08.25	Neuronetics Reports Second Quarter 2025 Financial and Operating Results
05.08.25	Neuronetics, Inc. Provides Earnings Guidance for the Third Quarter and Full Year Ending December 31, 2025
04.08.25	Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen MarketScreener Artikel MarketScreener Analysen Trading-Ideen

Andere Sprachen Neuronetics, Inc.

Aktien

A2JPMY

US64131A1051

STIM

Medizinische Ausrüstung

Andere Sprachen

Filter